Regeneron gets fast-track status for IL-1 Trap

By Elaine Rigoli

Tampa, Fla., May 31 - Regeneron Pharmaceuticals, Inc. announced Wednesday that the Food and Drug Administration has granted fast-track designation to the IL-1 Trap program for the improvement of chronic inflammation in patients with CIAS1-associated periodic syndromes, a spectrum of rare genetic disorders.

The fast-track designation is designed to facilitate the development and potentially expedite the review of new therapeutic medicines intended to treat serious conditions for which there is an unmet medical need.

In April, Regeneron announced the completion of enrollment in the pivotal study.

The company said it expects top-line efficacy data from this pivotal trial by the end of 2006.

Based in Tarrytown, N.Y., Regeneron is a biopharmaceutical company that develops therapeutic medicines for the treatment of serious medical conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.